| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7518649 | Journal of Clinical Epidemiology | 2018 | 26 Pages |
Abstract
Nonrandomized data were used for 7% of EMA drug approvals. Larger effect sizes were associated with greater likelihood of approval based on nonrandomized data alone. We did not find a clear treatment effect threshold for drug approval without RCT evidence.
Related Topics
Health Sciences
Medicine and Dentistry
Public Health and Health Policy
Authors
Benjamin Djulbegovic, Paul Glasziou, Farina A. Klocksieben, Tea Reljic, Magali VanDenBergh, Rahul Mhaskar, John P.A. Ioannidis, Iain Chalmers,